VEGFR-2 Protein, Human (HEK293, His)

VEGFR-2 is a tyrosine-protein kinase of the cell surface receptors of VEGFA, VEGFC, and VEGFD that mediates activation of the MAPK1/ERK2, MAPK3/ERK1, and MAP kinase signaling pathways, as well as the AKT1 signaling pathway. VEGFR-2 can promote the proliferation, survival, migration and differentiation of endothelial cells. Overexpression of VEGFR-2 is associated with the development of tumors. VEGFR-2 Protein, Human (HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Human (HEK293, His) is 745 a.a., with molecular weight of 84-140 kDa.

VEGF receptors (VEGFRs) are receptors for vascular endothelial growth factor (VEGF), and there are three main subtypes, VEGFR-1, VEGFR-2, and VEGFR-3. VEGFR-2 acts as a tyrosine-protein kinase of the cell surface receptor for VEGFA, VEGFC and VEGFD, and plays an important role in angiogenesis, vascular development, vascular permeability and embryonic hematopoiesis. It can promote the proliferation, survival, migration and differentiation of endothelial cells. Promote actin cytoskeleton recombination. VEGFR-2 regulates VEGFR-1 (FLT1) and VEGFR-3 (FLT40) signaling by forming heterodimers. VEGFR-2 mediates the activation of ,MAPK1/ERK2, MAPK3/ERK1 and MAP kinase signaling pathways, as well as the AKT1 signaling pathway. It mediates phosphorylation of the phosphatidylinositol 3-kinase regulatory subunit PIK3R1, recombination of actin cytoskeleton and activation of PTK2/FAK1. Vegfa-mediated induction of NOS2 and NOS3 is required, resulting in endothelial cell production of the signaling molecule nitric oxide (NO). Phosphorylated PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1, and SRC. Overexpression of VEGFR-2 is associated with tumorigenesis^{[1][2][3][4][5][6]}.

Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED₅₀for this effect is 9-160 ng/mL in the presence of 10 ng/mL recombinant human VEGF165.

• 
  Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED₅₀ for this effect is 9.805 ng/mL in the presence of 10 ng/mL recombinant human VEGF165, corresponding to a specific activity is 1.020×10⁵ units/mg.

Human

HEK293

C-His

AAI31823.1 (A20-E764)

3791  [NCBI]

ASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGITRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSHAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLE

84-140 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4 or 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.